RNAZ

Transcode Therapeutics Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 1/10
  • Momentum↓ 3/10
Transcode Therapeutics sales and earnings growth
RNAZ Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -31.92%
  • FCF Y/Y↑ 8.53%
Transcode Therapeutics gross and profit margin trends
RNAZ Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↑ 3205.40%
Transcode Therapeutics net debt vs free cash flow
RNAZ Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -3431.1

Transcode Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗